The article entitled “N6‐methyladenosine modification inhibits SLC7A11 mRNA deadenylation and enhances ferroptosis resistance in hepatoblastoma” by Liu et al., published in Clinical and Translational Medicine in May 2022, offers up convincing evidence that SLC7A11 overexpression attributes to enhanced N6‐methyladenosine (m6A) presence in its mRNA transcripts. Here, SLC7A11 is linked to hepatoblastoma.